Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data

American Journal of Gastroenterology

Volumn 112, Issue 4, 2017, Pages 581-587

  Kabbany, Mohammad Nasser ^a   Selvakumar, Praveen Kumar Conjeevaram ^a   Watt, Kymberly ^b   Lopez, Rocio ^a   Akras, Zade ^a   Zein, Nizar ^a   Carey, William ^a   Alkhouri, Naim ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ALCOHOL CONSUMPTION; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; INSULIN RESISTANCE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; UNITED STATES; COMPLICATION; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITION; SEVERITY OF ILLNESS INDEX;

DIABETES MELLITUS; FEMALE; HUMANS; INSULIN RESISTANCE; LIVER CIRRHOSIS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; NUTRITION SURVEYS; OBESITY; PREVALENCE; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 85012874026     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2017.5     Document Type: Review

References (30)

1. Brown GT, Kleiner DE. Histopathology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Metabolism 2016; 65: 1080-6.
2. Angulo P, Kleiner DE, Dam-Larsen S et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 389-397.e10.
3. Ekstedt M, Hagström H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61: 1547-54.
4. Browning JD, Szczepaniak LS, Dobbins R et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-95.
5. Younossi ZM, Stepanova M, Afendy M et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.e1.
6. Lazo M, Hernaez R, Eberhardt MS et al. Prevalence of nonalcoholic fatty liver disease in the United States: the third national health and nutrition examination survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45.
7. Matteoni C, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
8. Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-31.
9. Castera L. Noninvasive evaluation of nonalcoholic fatty liver disease. Semin Liver Dis 2015; 7: 45-7.
10. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.
11. Kruger FC, Daniels CR, Kidd M et al. APRI: a simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/ NASH. South Afr Med J 2011; 101: 477-80.
12. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43: 1317-25.
13. Shah AG, Lydecker A, Murray K et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7: 1104-12.
14. Angulo P, Hui JM, Marchesini G et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 2007; 45: 846-54.
15. Angulo P, Bugianesi E, Bjornsson ES et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-789.e4.
16. CDC. National Health and Nutrition Examination Survey, 2013-2014. National Health Statistics Report 2014, 2013-4.
17. Scaglione S, Kliethermes S, Cao G et al. The epidemiology of cirrhosis in the United States: a population-based study. J Clin Gastroenterol 2015; 49: 690-6.
18. Calès P, Lainé F, Boursier J et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50: 165-73.
19. Lieber CS, Weiss DG, Morgan TR et al. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006; 101: 1500-8.
20. Kim D, Kim WR, Kim HJ et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-65.
21. Johnson CL, Paulose-Ram R, Ogden CL et al. National Health and Nutrition Examination Survey: analytic guidelines, 1999-2010. Vital Health Stat 2013; 2: 1999-2010.
22. Johnson CL, Paulose-Ram R, Ogden CL et al. National health and nutrition examination survey: analytic guidelines, 1999-2010. Vital Health Stat 2013; 2: 1-24.
23. Howden L, Meyer J. Age and sex composition: 2010. 2010 census briefs. US Census Bureau 2011, 1-15.
24. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-21.
25. Charlton MR, Burns JM, Pedersen RA et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141: 1249-53.
26. Marengo A, Jouness RIK, Bugianesi E. Progression and natural history of nonalcoholic fatty liver disease in adults. Clin Liver Dis 2016; 20: 313-24.
27. Ascha MS, Hanouneh IA, Lopez R et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972-8.
28. Mehal WZ, Schuppan D. Anti fibrotic therapies in the liver. Semin Liver Dis 2015; 35: 184-98.
29. Rinella M, Charlton M. The globalization of nonalcoholic fatty liver disease: prevalence and impact on world health. Hepatology 2016; 64: 19-22.
30. Kuklina EV, Carroll MD, Shaw KM et al. Trends in high LDL cholesterol, cholesterol-lowering medication use, and dietary saturated-fat intake: United States, 1976-2010. NCHS Data Brief 2013; 117: 1-8.